Global Peptide Therapeutics Industry: Key Statistics and Insights in 2025-2033

Summary:

• The global peptide therapeutics market size reached USD 46.2 Billion in 2024.
• The market is expected to reach USD 91.9 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033.
• North America leads the market, accounting for the largest peptide therapeutics market share.
• Innovative holds the majority of the market share in the type segment. 
• In-house dominates the peptide therapeutics industry.
• Liquid phase peptide synthesis is the leading segment in the market, driven by its flexibility and efficiency in producing a wide range of peptide sequences.
• Parenteral represents the biggest application segment.
• Cancer exhibits a clear dominance in the market.
• The increasing prevalence of chronic diseases and cancer is a primary driver of the peptide therapeutics market.
• Technological innovation in synthesis and the growing focus on personalized medicine are reshaping the peptide therapeutics market.

Industry Trends and Drivers:

• Rising prevalence of chronic diseases and cancer:

The rise of undress sicknesses including diabetes, cardiovascular disorders, and diseases related to cancer among the population also becomes one of the main drives for the market advancement. These conditions demand specific treatment, and peptides are known for their high selectivity and low side effects compared to conventional mid-sized compounds. Peptides can be used in selective killing of cancer cells and has fewer side effects after compared to most chemotherapy drugs. Further, peptides find a significant use in metabolic and hormonal disorders since they can either copy or control the body’s routine functions to increase the effectiveness of treatment. The increasing incidence of life-style diseases such as diabetes makes peptide therapy relevant; peptides affect the action of insulin or glucose.

• Technological innovations in peptide synthesis:

The customary approaches to synthesizing peptides were inefficient and mostly cumbersome, thereby causing high costs and low adoption. However, introduction of SPPS and automated synthesis have risen and revolutionized the market displacing the traditional cottage industry approach to the synthesis of peptides. The benefits of these advancements are reigniting increased yields and higher purities of the produced peptides and the possibility of synthesizing multifunctional and more complex peptides. Furthermore, novel modalities that include physical and chemical methodologies like microwave assisted synthesis and click chemistry are also helping in discovery of novel peptide based therapeutic moieties. Manufacturing is being done systematically, therefore making it easier for people to access peptide therapies. Advancements in synthetic chemistry are enabling the existence of a large pipeline of peptide drugs to address numerous therapeutic applications.

• Growing focus on personalized medicine:

Healthcare is moving away from a one-size-fits-all approach, driving the demand for targeted and customized therapies. Peptides, due to their unique ability to interact with specific biological pathways, allow for the development of tailored therapies that address patients’ unique genetic and molecular profiles. This customization enhances therapeutic efficacy and minimizes adverse effects, making peptide therapies particularly attractive for conditions such as cancer, where individual tumor characteristics can greatly influence treatment outcomes. The trend toward personalized medicine is supported by advances in genomics and proteomics, which facilitate the identification of new peptide targets. Healthcare systems are recognizing the value of personalized treatment strategies, leading to greater investment in peptide therapies to spur further innovation in this field.

Request for a sample copy of this report: https://www.imarcgroup.com/peptide-therapeutics-market/requestsample

Peptide Therapeutics Market Report Segmentation:

Breakup By Type:

• Innovative
• Generic

Innovative exhibits a clear dominance in the market, driven by the advanced therapeutic potential and higher investment in research operations.

Breakup By Type of Manufacturer:

• Outsourced
• In-house

In-house represents the largest segment due to the preference of companies to maintain control over production quality and intellectual property.

Breakup By Synthesis Technology:

• Solid Phase Peptide Synthesis
• Liquid Phase Peptide Synthesis
• Hybrid Technology

Liquid phase peptide synthesis holds the biggest market share attributed to its flexibility and efficiency in producing a wide range of peptide sequences.

Breakup By Routes of Administration:

• Parenteral
• Oral
• Others

Parenteral accounts for the majority of the market share, as it offers direct and efficient delivery of peptides that are otherwise poorly absorbed orally.

Breakup By Application:

• Gastrointestinal Disorders
• Neurological Disorders
• Metabolic Disorders
• Cancer
• Others

Cancer represents the largest segment accredited to the rising demand for targeted therapies and the increasing investment in oncology research.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the market owing to its advanced healthcare infrastructure, high investments in research, and the presence of major pharmaceutical companies.

Top Peptide Therapeutics Market Leaders:

The peptide therapeutics market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Amgen Inc.
• Apitope International NV
• Arch Biopartners Inc.
• AstraZeneca plc
• Circle Pharma Inc.
• Corden Pharma GmbH
• F. Hoffmann-La Roche AG
• Ipsen Group
• Lonza Group AG
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceuticals Industries Ltd.
• Zealand Pharma A/S

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145